Clinical Trial VICCBRE1356


A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer

Principal Investigator(s)

Vandana Abramson


  • Protocol No. VICCBRE1356
  • Open Date: 11/07/2013
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To determine clinical benefit rate, defined as the proportion of evaluable patients with androgen receptor-positive (AR+), triple-negative breast cancer (TNBC) with a best response of complete response (CR), partial response (PR), or stable disease (SD) >/= 16 weeks.
  • Disease Sites:
  • Therapies: Hormonal Therapy
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01889238
  • Secondary Protocol No: MDV3100-11



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.